These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36881997)

  • 1. Flashback Foreword: Anti-HER2 Monoclonal Antibody as a Single Agent.
    Goodwin PJ
    J Clin Oncol; 2023 Mar; 41(8):1499-1500. PubMed ID: 36881997
    [No Abstract]   [Full Text] [Related]  

  • 2. Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy.
    Friedberg JW
    J Clin Oncol; 2023 Jan; 41(2):151-152. PubMed ID: 36603540
    [No Abstract]   [Full Text] [Related]  

  • 3. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
    Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
    Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of an antitumor drug-delivery system based on anti-HER2 antibody-conjugated BSA nanoparticles.
    Zhang N; Zhang J; Wang P; Liu X; Huo P; Xu Y; Chen W; Xu H; Tian Q
    Anticancer Drugs; 2018 Apr; 29(4):307-322. PubMed ID: 29381491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer.
    Musolino A; Boggiani D; Pellegrino B; Zanoni D; Sikokis A; Missale G; Silini EM; Maglietta G; Frassoldati A; Michiara M
    Crit Rev Oncol Hematol; 2020 May; 149():102927. PubMed ID: 32172224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of anti-HER2 monoclonal antibodies.
    Baselga J; Albanell J
    Ann Oncol; 2001; 12 Suppl 1():S35-41. PubMed ID: 11521720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
    Sakamoto G; Mitsuyama S
    Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
    [No Abstract]   [Full Text] [Related]  

  • 11. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
    Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
    Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
    Poncet B; Bachelot T; Colin C; Orfeuvre H; Ganne C; Péaud PY; Jacquin JP; Salles B; Tigaud JD; Méchin-Crétinon I; Maréchal F; Trillet-Lenoir V
    Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):162-3. PubMed ID: 17357239
    [No Abstract]   [Full Text] [Related]  

  • 13. [Herceptin and its therapeutic strategy in patients with breast cancer overexpressing HER2].
    Tajima T; Suzuki Y; Tokuda Y
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1132-7. PubMed ID: 12145992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer.
    Wong WM
    Cancer Pract; 1999; 7(1):48-50. PubMed ID: 9893005
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.
    Li XF; Liu CF; Rao GW
    Curr Med Chem; 2021; 28(17):3339-3360. PubMed ID: 32900344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.
    Sawaki M; Ito Y; Tada K; Mizunuma N; Takahashi S; Horikoshi N; Kasumi F; Akiyama F; Sakamoto G; Imai T; Nakao A; Hatake K
    Tumori; 2004; 90(1):40-3. PubMed ID: 15143970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
    Pegram M; Slamon D
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):13-9. PubMed ID: 11049052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.